Ascitic Calprotectin as an early predictor of hepatocellular carcinoma in patients with cirrhotic ascites
| Autor: | Amr Shaaban Hanafy, Ahmed A Alnagar, Mohamed Sorour Mohamed |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Liver Cirrhosis Male Cancer Research medicine.medical_specialty Cirrhosis Carcinoma Hepatocellular Gastroenterology S100A9 S100A8 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Ascites medicine Biomarkers Tumor Ascitic Fluid Humans Creatinine medicine.diagnostic_test business.industry Liver Neoplasms General Medicine Middle Aged medicine.disease digestive system diseases 030104 developmental biology Oncology chemistry Liver 030220 oncology & carcinogenesis Hepatocellular carcinoma Female medicine.symptom Calprotectin Liver function tests business Leukocyte L1 Antigen Complex |
| Zdroj: | Journal of cancer research and clinical oncology. 146(12) |
| ISSN: | 1432-1335 |
| Popis: | Calprotectin is a heterodimer formed by S100A8 and S100A9 proteins which are enhanced during hepatic carcinogenesis and the increased expression of both proteins promotes malignant progression of hepatocellular carcinoma. The potential correlation between ascitic Calprotectin and HCC was not studied. 100 patients were stratified into a case group which enrolled 50 patients with cirrhotic ascites and documented HCC and a control group consisted of 50 patients with cirrhotic ascites without HCC. They were evaluated by liver function tests, abdominal ultrasound and routine ascitic fluid examination including ascetic Calprotectin and results were validated in another group (n = 100). Calprotectin level was significantly higher in the HCC group with insignificant difference regarding total cell count, PNLs, ascitic albumin, LDH, CEA and SAAG. It correlated with serum creatinine (r = 0.245, p = 0.014) and number of focal hepatic lesions (r = 0.309, p = 0.002). In the validation group, 28 patients had elevated ascitic Calprotectin of which 21 patients had developed HCC (75%) after a mean period of 3.8 ± 1.54 months. A cut of value 126 ng/ml was accurate to predict HCC in liver cirrhosis with ascites with a sensitivity of 93.3% specificity 94%, AUC 0.950, Youden’s J value = 0.873, p = 0.0001. Ascitic Calprotectin may offer an easy, affordable marker that can predict the early occurrence of HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink